Mod­er­na piv­ots from a buy­out to a plat­form tech al­liance as its strug­gling part­ner scores an­oth­er mar­quee al­ly

A day af­ter pluck­ing up a tool­mak­er for its man­u­fac­tur­ing ops in an $85 mil­lion buy­out, Mod­er­na’s team turned right back around with a tech al­liance the big biotech be­lieves can pos­si­bly of­fer its mR­NA pipeline a sig­nif­i­cant boost.

In one of the lat­est pre-#JPM23 news items to hit, strug­gling Cy­tomX Ther­a­peu­tics is pick­ing up a $35 mil­lion up­front to kick off a joint pre­clin­i­cal ef­fort to see how the small­er biotech’s plat­form tech can do in mask­ing the pres­ence of an mR­NA ther­a­peu­tic un­til it lands right at the dis­ease tar­get.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER